Runnymede Capital Advisors Inc. Makes New $233,000 Investment in iShares Biotechnology ETF (NASDAQ:IBB)

Runnymede Capital Advisors Inc. bought a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,762 shares of the financial services provider’s stock, valued at approximately $233,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets lifted its stake in iShares Biotechnology ETF by 29.3% in the third quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock worth $346,561,000 after purchasing an additional 538,899 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in iShares Biotechnology ETF by 32.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after buying an additional 164,000 shares during the period. Main Management ETF Advisors LLC lifted its stake in shares of iShares Biotechnology ETF by 2.5% during the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after purchasing an additional 14,535 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of iShares Biotechnology ETF in the 4th quarter valued at about $55,010,000. Finally, Gray Foundation boosted its holdings in shares of iShares Biotechnology ETF by 25.2% in the 4th quarter. Gray Foundation now owns 164,872 shares of the financial services provider’s stock valued at $21,798,000 after buying an additional 33,179 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Stock Up 0.6 %

NASDAQ IBB opened at $133.58 on Friday. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57. The company has a 50 day moving average price of $136.23 and a 200 day moving average price of $139.39. The firm has a market cap of $6.09 billion, a PE ratio of 27.83 and a beta of 0.77.

iShares Biotechnology ETF Increases Dividend

The firm also recently disclosed a dividend, which was paid on Friday, March 21st. Stockholders of record on Tuesday, March 18th were issued a dividend of $0.1212 per share. The ex-dividend date of this dividend was Tuesday, March 18th. This is a positive change from iShares Biotechnology ETF’s previous dividend of $0.06.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.